Literature DB >> 15884115

Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines.

Nisana Tepsiri1, Liengchai Chaturat, Banchob Sripa, Wises Namwat, Sopit Wongkham, Vajarabhongsa Bhudhisawasdi, Wichittra Tassaneeyakul.   

Abstract

AIM: To study the effect of a number of chemotherapeutic drugs on five human intrahepatic cholangiocarcinoma (CCA) cell lines. The expressions of genes that have been proposed to influence the resistance of chemotherapeutic drugs including thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), glutathione-S-transferase P1 (GSTP1), multidrug resistance protein (MDR1) and multidrug resistance-associated proteins (MRPs) were also determined.
METHODS: Five human CCA cell lines (KKU-100, KKU-M055, KKU-M156, KKU-M214 and KKU-OCA17) were treated with various chemotherapeutic drugs and growth inhibition was determined by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay. Semi-quantitative levels of gene expression were determined by a reverse transcriptase polymerase chain reaction (RT-PCR). Results of IC(50) values and the ratios of gene expression were analyzed by linear regression to predict their relationship.
RESULTS: Among five CCA cell lines, KKU-M055 was the most sensitive cell line towards all chemotherapeutic drugs investigated, particularly taxane derivatives with IC(50) values of 0.02-3 nmol/L, whereas KKU-100 was apparently the least sensitive cell line. When compared to other chemotherapeutic agents, doxorubicin and pirarubicin showed the lowest IC(50) values (<5 mumol/L) in all five CCA cell lines. Results from RT-PCR showed that TS, MRP1, MRP3 and GSTP1 were highly expressed in these five CCA cell lines while DPD and MRP2 were only moderately expressed. It should be noted that MDR1 expression was detected only in KKU-OCA17 cell lines. A strong correlation was only found between the level of MRP3 expression and the IC(50) values of etoposide, doxorubicin and pirarubicin (r = 0.86-0.98, P<0.05).
CONCLUSION: Sensitivity to chemotherapeutic agents is not associated with the histological type of CCA. Choosing of the appropriate chemotherapeutic regimen for the treatment of CCA requires knowledge of drug sensitivity. MRP3 was correlated with resistance of CCA cell lines to etoposide, doxorubicin and pirarubicin, whereas other chemotherapeutic drugs showed no association. The role of this multidrug resistance-associated protein, MRP3, in chemotherapeutic resistance in CCA patients needs to be further investigated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15884115      PMCID: PMC4305909          DOI: 10.3748/wjg.v11.i18.2748

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  47 in total

1.  An increasing incidence of cholangiocarcinoma: why?

Authors:  Laurie Blendis; Zamir Halpern
Journal:  Gastroenterology       Date:  2004-09       Impact factor: 22.682

Review 2.  Study of suboptimum treatment response: lessons from breast cancer.

Authors:  Per Eystein Lønning
Journal:  Lancet Oncol       Date:  2003-03       Impact factor: 41.316

3.  Reversal effects of antifungal drugs on multidrug resistance in MDR1-overexpressing HeLa cells.

Authors:  N Iida; K Takara; N Ohmoto; T Nakamura; T Kimura; A Wada; M Hirai; T Sakaeda; K Okumura
Journal:  Biol Pharm Bull       Date:  2001-09       Impact factor: 2.233

4.  Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves.

Authors:  M Nishiyama; W Yamamoto; J S Park; R Okamoto; H Hanaoka; H Takano; N Saito; M Matsukawa; T Shirasaka; M Kurihara
Journal:  Clin Cancer Res       Date:  1999-09       Impact factor: 12.531

5.  Resistant mechanisms of anthracyclines--pirarubicin might partly break through the P-glycoprotein-mediated drug-resistance of human breast cancer tissues.

Authors:  T Kubota; T Furukawa; H Tanino; A Suto; Y Otan; M Watanabe; T Ikeda; M Kitajima
Journal:  Breast Cancer       Date:  2001       Impact factor: 4.239

6.  Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells.

Authors:  Gergely Szakács; Jean-Philippe Annereau; Samir Lababidi; Uma Shankavaram; Angela Arciello; Kimberly J Bussey; William Reinhold; Yanping Guo; Gary D Kruh; Mark Reimers; John N Weinstein; Michael M Gottesman
Journal:  Cancer Cell       Date:  2004-08       Impact factor: 31.743

7.  Epirubicin, cisplatin, and protracted infusion of 5-FU (ECF) in advanced intrahepatic cholangiocarcinoma.

Authors:  Myung Ah Lee; In Sook Woo; Jin-Hyoung Kang; Young Seon Hong; Kyung Shik Lee
Journal:  J Cancer Res Clin Oncol       Date:  2004-02-28       Impact factor: 4.553

8.  Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells.

Authors:  Makiko Taniai; Annette Grambihler; Hajime Higuchi; Nate Werneburg; Steve F Bronk; Daniel J Farrugia; Scott H Kaufmann; Gregory J Gores
Journal:  Cancer Res       Date:  2004-05-15       Impact factor: 12.701

Review 9.  A review and update on cholangiocarcinoma.

Authors:  Matthew J Olnes; Rodrigo Erlich
Journal:  Oncology       Date:  2004       Impact factor: 2.935

10.  High expression of thymidylate synthase leads to resistance to 5-fluorouracil in biliary tract carcinoma in vitro.

Authors:  K Habara; T Ajiki; T Kamigaki; T Nakamura; Y Kuroda
Journal:  Jpn J Cancer Res       Date:  2001-10
View more
  36 in total

1.  Apoptotic activity of caged xanthones from Garcinia hanburyi in cholangiocarcinoma cell lines.

Authors:  Chariya Hahnvajanawong; Wongwarut Boonyanugomol; Tapanawan Nasomyon; Watcharin Loilome; Nisana Namwat; Natthinee Anantachoke; Wichittra Tassaneeyakul; Banchob Sripa; Wises Namwat; Vichai Reutrakul
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

Review 2.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

3.  Radiation- and chemoinduced multidrug resistance in colon carcinoma cells.

Authors:  Detlef Bartkowiak; Michael Stempfhuber; Thomas Wiegel; Dirk Bottke
Journal:  Strahlenther Onkol       Date:  2009-12       Impact factor: 3.621

4.  The combination of BET and PARP inhibitors is synergistic in models of cholangiocarcinoma.

Authors:  Samuel C Fehling; Aubrey L Miller; Patrick L Garcia; Rebecca B Vance; Karina J Yoon
Journal:  Cancer Lett       Date:  2019-10-09       Impact factor: 8.679

Review 5.  Cholangiocarcinoma: from molecular biology to treatment.

Authors:  Ana F Brito; Ana M Abrantes; João C Encarnação; José G Tralhão; Maria F Botelho
Journal:  Med Oncol       Date:  2015-10-01       Impact factor: 3.064

Review 6.  Regulation of hepatic ABCC transporters by xenobiotics and in disease states.

Authors:  Xinsheng Gu; Jose E Manautou
Journal:  Drug Metab Rev       Date:  2010-08       Impact factor: 4.518

7.  Interaction of oxazaphosphorines with multidrug resistance-associated protein 4 (MRP4).

Authors:  Jing Zhang; Ka-Yun Ng; Paul C Ho
Journal:  AAPS J       Date:  2010-04-20       Impact factor: 4.009

8.  Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells.

Authors:  Hiroaki Sugiyama; Kenichiro Onuki; Kazunori Ishige; Nobue Baba; Tetsuya Ueda; Sachiko Matsuda; Kaoru Takeuchi; Masafumi Onodera; Yasuni Nakanuma; Masayuki Yamato; Masakazu Yamamoto; Ichinosuke Hyodo; Junichi Shoda
Journal:  J Gastroenterol       Date:  2011-02-18       Impact factor: 7.527

Review 9.  A review of systemic therapy in biliary tract carcinoma.

Authors:  Holger Jansen; Ulrich-Frank Pape; Nalân Utku
Journal:  J Gastrointest Oncol       Date:  2020-08

10.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Authors:  Jesus M Banales; Vincenzo Cardinale; Guido Carpino; Marco Marzioni; Jesper B Andersen; Pietro Invernizzi; Guro E Lind; Trine Folseraas; Stuart J Forbes; Laura Fouassier; Andreas Geier; Diego F Calvisi; Joachim C Mertens; Michael Trauner; Antonio Benedetti; Luca Maroni; Javier Vaquero; Rocio I R Macias; Chiara Raggi; Maria J Perugorria; Eugenio Gaudio; Kirsten M Boberg; Jose J G Marin; Domenico Alvaro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-20       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.